Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03040973 · ClinicalTrials.gov registry record · Phase 2
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
A Phase 2 study of Advanced Solid Tumors Which Are cMET-dependent, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 15
- Study locations
NCT03040973 is a Phase 2 study of Advanced Solid Tumors Which Are cMET-dependent that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 29 participants. The trial reports 15 study locations across 10 states.
The verdict
NCT03040973, a Phase 2 study of Advanced Solid Tumors Which Are cMET-dependent, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment alone in a Novartis sponsored study
Conditions Studied
Interventions
- DRUG Capmatinib
- DRUG Osimertinib
- DRUG Gefitinib
- DRUG Nazartinib
Study Locations (15)
Other
- Novartis Investigative Site - Leuven
- Novartis Investigative Site - Copenhagen
- Novartis Investigative Site - Hanover
- Novartis Investigative Site - Singapore
- Novartis Investigative Site - Seoul
- Novartis Investigative Site - Madrid
Massachusetts
- Massachusetts General Hospital - Boston
Alberta
- Novartis Investigative Site - Edmonton
Shanghai Municipality
- Novartis Investigative Site - Shanghai
Yunnan
- Novartis Investigative Site - Kunming
Cote D Or
- Novartis Investigative Site - Dijon
North Rhine-Westphalia
- Novartis Investigative Site - Cologne
MI
- Novartis Investigative Site - Milan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-08-23 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03040973
The ClinicalTrials.gov registry entry for NCT03040973 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors Which Are cMET-dependent appearing as the primary indexed condition, and to 4 interventions - of which Capmatinib is the first listed.
NCT03040973 reports 15 study locations spanning 10 distinct geographic areas - top geographies include Other, Massachusetts, Alberta.
Frequently Asked Questions
What is clinical trial NCT03040973 about?
NCT03040973 is a clinical study titled "Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone". The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment a...
What is the current status of trial NCT03040973?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2017-08-23. Estimated completion is 2027-07-30.
What conditions does trial NCT03040973 study?
This clinical trial studies the following conditions: Advanced Solid Tumors Which Are cMET-dependent.
What interventions are being tested in trial NCT03040973?
The interventions under investigation include: Capmatinib (DRUG), Osimertinib (DRUG), Gefitinib (DRUG), Nazartinib (DRUG).
Who is sponsoring clinical trial NCT03040973?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03040973 being conducted?
This trial has 15 study locations across Massachusetts, Alberta, Shanghai Municipality, Yunnan, Cote D Or. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.